An indigenously developed gene therapy for blood cancers is making waves in India’s medical community, boasting an impressive 73% response rate among patients. As per clinical trials published in The Lancet Haematology, this CAR T-cell therapy is offering a cost-effective alternative to existing treatments in developed countries.
About the Author
